19
December 2024
Aptamer Group
plc
("Aptamer", the "Company" or the "Group")
New Development
Contract
Agreement worth up to
£155,000 and potential for significant IP
transfer fee payment upon success
Aptamer Group plc (AIM: APTA),
the developer of novel Optimer® binders to
enable innovation in the life sciences
industry, today announces the signing of a new development contract
with a rare disease biopharmaceutical company. The agreement, worth
up to £155,000, focuses on developing two Optimer binders as
critical reagents for therapeutic monitoring. Upon successful
development, Aptamer could receive a significant undisclosed IP
transfer fee for the use of the Optimers in clinical trial
monitoring.
Dr
Arron Tolley, Chief Executive Officer of Aptamer Group,
commented: "This agreement
further demonstrates our strategic model of leveraging
fee-for-service revenue for the development of Optimer binders and
potential licensing revenues.
With a healthy pipeline and
increasing traction among both new and repeat customers, we are
demonstrating our commercial strategy. These advancements align
with our broader vision of driving shareholder value by pairing
fee-for-service income with scalable licensing opportunities. We
remain focused on delivering on our growth objectives and look
forward to sharing updates on our continued progress."
- Ends -
For
further information, please contact:
|
Aptamer Group plc
Arron Tolley, Chief Executive
Officer
|
+44 (0) 1904 217
404
|
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368
3550
|
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
|
Northstar Communications Limited - Investor
Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
About Aptamer Group plc
Aptamer Group is a leading global
developer of aptamer-based ligands that help scientists remove the
limits to discovery and innovation. Leveraging a proprietary
discovery and development platform, Aptamer delivers custom
affinity ligands, supported with a complete suite of
characterisation and validatory assays that enhance the translation
of its binders and optimise scientific outcomes for
customers.
Aptamer's cutting-edge technology
spans healthcare, research, personal care, and industrial
processes, delivering new affinity solutions for novel targets,
advanced diagnostics, and precision therapies. By working with
industry leaders in pharmaceutical, biotechnology, personal health,
academic, and clinical research sectors, Aptamer is accelerating
science through the custom development of tools and
therapies.
To register for news alerts by email
go to https://aptamergroup.com/investors/investor-news-email-alerts/